Seqirus announces FDA approval of Fluad for seasonal influenza

November 25, 2015

Seqirus announced today that the US Food and Drug Administration has approved Fluad (Influenza Vaccine, Adjuvanted) to help protect those aged 65 years and older against seasonal influenza. Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older.

Previous Article
Meridian Health Plan wins 2015 Top Workplaces award
Meridian Health Plan wins 2015 Top Workplaces award

Meridian Health Plan has been awarded a 2015 Top Workplaces honor by the Detroit Free Press. The Top Workpl...

Next Article
BioLight signs joint financing agreement with two Asia-based venture capital firms
BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercia...